119-S-1784 Journalist Public Summary

Public Summary — Mapping America’s Pharmaceutical Supply (MAPS) Act, S. 1784

1) Headline Summary: A bipartisan plan to map and monitor the drug supply chain—so the government can spot risks early, reduce shortages, and strengthen national security.

2) What It Does: The bill tells Health and Human Services (HHS) to keep an up‑to‑date Essential Medicines List and to analyze where the ingredients and finished drugs come from, who makes them, and where the weak points are. It requires a full supply‑chain mapping effort that uses data analytics to flag vulnerabilities, plus recurring reports to Congress. The Defense Department must twice a year disclose drugs it buys that rely on Chinese ingredients or manufacturing. The bill also directs strong cybersecurity and protects confidential business information while agencies share data. Why it matters: Drug shortages and heavy reliance on a few foreign sources can delay care, raise costs, and pose risks for hospitals, patients with chronic conditions, and military readiness.

• 3) Who’s For It: The sponsors—Sens. Gary Peters (D‑MI), James Lankford (R‑OK), Joni Ernst (R‑IA), Tom Cotton (R‑AR), Tim Kaine (D‑VA), Angus King (I‑ME), and Rick Scott (R‑FL)—frame it as a practical, bipartisan step to prevent shortages and reduce national‑security exposure.
• Supporters’ case: Clear visibility into where medicines and ingredients are made helps the government and industry act before a shortage hits; mapping also guides investments in resilient, domestic, or allied production.

• 4) Who’s Against It: No formal opposition is listed yet, but likely critics could include some manufacturers and trade groups worried about data‑sharing burdens or costs; privacy advocates focused on handling of sensitive business data; and fiscal conservatives concerned about creating new federal systems.
• Opponents’ case: Mapping and reporting could be duplicative or expensive; government data collection may risk leaks or misuse; and singling out certain foreign sources could disrupt supply or invite retaliation.

5) What’s Next: The bill was introduced on May 15, 2025 and referred to the Senate Health, Education, Labor, and Pensions (HELP) Committee. HELP held a hearing on March 19, 2026. Next typical steps are a committee markup and vote; if it advances, the full Senate would consider it, and then the House would take it up. If both chambers pass the same text, it would go to the President for signature or veto.